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Conventional Dendritic Cells Mount a Type I IFN Response
against Candida spp. Requiring Novel Phagosomal
TLR7-Mediated IFN-b Signaling
Christelle Bourgeois,* Olivia Majer,* Ingrid E. Frohner,* Iwona Lesiak-Markowicz,*
Kwang-Soo Hildering,* Walter Glaser,* Silvia Stockinger,†,1 Thomas Decker,†
Shizuo Akira,‡ Mathias Mu¨ller,x and Karl Kuchler*
Human fungal pathogens such as the dimorphic Candida albicans or the yeast-like Candida glabrata can cause systemic candidiasis
of high mortality in immunocompromised individuals. Innate immune cells such as dendritic cells and macrophages establish the
first line of defense against microbial pathogens and largely determine the outcome of infections. Among other cytokines, they
produce type I IFNs (IFNs-I), which are important modulators of the host immune response. Whereas an IFN-I response is
a hallmark immune response to bacteria and viruses, a function in fungal pathogenesis has remained unknown. In this study, we
demonstrate a novel mechanism mediating a strong IFN-b response in mouse conventional dendritic cells challenged by Candida
spp., subsequently orchestrating IFN-a/b receptor 1-dependent intracellular STAT1 activation and IFN regulatory factor (IRF) 7
expression. Interestingly, the initial IFN-b release bypasses the TLR 4 and TLR2, the TLR adaptor Toll/IL-1R domain-containing
adapter-inducing IFN-b and the b-glucan/phagocytic receptors dectin-1 and CD11b. Notably, Candida-induced IFN-b release is
strongly impaired by Src and Syk family kinase inhibitors and strictly requires completion of phagocytosis as well as phagosomal
maturation. Strikingly, TLR7, MyD88, and IRF1 are essential for IFN-b signaling. Furthermore, in a mouse model of dissem-
inated candidiasis we show that IFN-I signaling promotes persistence of C. glabrata in the host. Our data uncover for the first time
a pivotal role for endosomal TLR7 signaling in fungal pathogen recognition and highlight the importance of IFNs-I in modulating
the host immune response to C. glabrata. The Journal of Immunology, 2011, 186: 3104–3112.
I
nvasive Candida infections are life-threatening clinical con-
ditions, primarily affecting immunosuppressed patient co-
horts and patients with defects in cellular immunity (1).
Mortalities associated with disseminated candidemia can exceed
30–40%, despite appropriate antifungal treatment. The dimorphic
Candida albicans and the inherently drug-tolerant yeast-likeCandida
glabrata constitute the most frequent causes of fungal infections in
humans (1).C. albicans can switch between a yeast and a filamentous
(hyphae) form upon host or environmental stimuli.
Initial colonization and subsequent development of disseminated
diseases are determined by the nature of the interaction of Candida
spp. with host immune cells and tissues (2). The rate of clearance by
the host immune surveillance versus the fungal fitness and growth
in organs and tissues determines the outcome such as fungal clear-
ance or host death. Early recognition of pathogens by immune cells
is mediated by dedicated pattern recognition receptors (PRRs), in-
cluding TLRs and C-type lectins expressed at the surface of innate
cells, mainly monocytes, macrophages, neutrophils, and dendritic
cells (DCs) (2). PRRs recognize microbe-specific pathogen-asso-
ciated molecular patterns (PAMPs) and trigger several intracellu-
lar signaling pathways to orchestrate a pathogen-specific as well
as cell-type–specific host immune response (3, 4).
The sugar polymers (e.g., chitin, b-D-glucans, and mannan) and
proteins forming the fungal cell surface are considered the prime
source of fungal PAMPs. Notably, b-D-glucans seem to be pref-
erential ligands for the dectin-1 receptor, which mediates fungal
recognition and signaling alone, as well as with the phospholi-
pomannan receptor TLR2 as a coreceptor. By contrast, mannose-
sensing receptors include the mannan receptor, TLR4, dectin-2,
Mincle, the SIGNR receptor family, and galectin3, whereas TLR6
in association with TLR2 mediates zymosan-induced signaling
(reviewed in Ref. 2). Deficiency in certain PRRs, including TLR4,
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TLR2, Mincle, dectin-1, or their intracellular signaling adaptors
such as MyD88 and CARD9 strongly impairs survival of mice to
Candida infections, emphasizing the essential role of early path-
ogen recognition for mounting efficient host immune responses
(4). Nevertheless, conflicting reports on individual contributions
of certain PRRs (reviewed in Refs. 2, 4) point to the enormous
underlying complexity.
In addition to cell surface PAMPs, nucleic acids from Candida
may also stimulate or modulate the dynamic host response during
infection. Indeed, dsDNA from C. albicans elicits cytokine release
in mice (5, 6) in a TLR9-dependent fashion (6). Moreover, ssRNA
induces a Th1 response normally associated with a protective role
(7).
Binding of fungal PAMPs to PRRs preludes phagocytosis and
stimulates the release of extracellular reactive oxygen species (8)
and specific cytokines, ultimately activating innate effector cells.
Among others, DCs are instrumental in relaying pathogen in-
formation from innate immunity to the adaptive response through
their ability to act as professional APCs. PAMP recognition
stimulates DCs to produce signal cytokines, including type I IFNs
(IFNs-I) through the so-called first-wave response (9). Extracel-
lular IFN-b subsequently activates its cognate receptor, IFN-a/b
receptor (IFNAR), in an autocrine/paracrine fashion, driving the
second-wave of IFN-a/b, which is considered a hallmark response
against many viral and bacterial pathogens (9). This massive re-
lease of IFN-I triggers the subsequent expression of IFN-I–stim-
ulated genes, many of which drive maturation of DCs both in vivo
and in vitro, thereby modulating the Th cell differentiation in
a pathogen-specific manner (9).
A lack of the functional IFNAR increases susceptibility of mice
to a number of viral and bacterial pathogens. However, in certain
cases, IFN-b can also cause deleterious effects for the host, cre-
ating a “yin-yang” situation for both the host and the pathogen
(10). Interestingly, Flt3-induced DCs release IFNs-I in response to
C. albicans (11), and unmethylated CpG motifs from Aspergillus
fumigatus induce IFN-a production through TLR9 activation in
human DCs (12). A recent report also suggests that IFNs-I con-
tribute to the response of mice to Cryptococcus neoformans and
Histoplasma capsulatum in vivo (13, 14). However, the mo-
lecular mechanisms by which Candida spp. induce the IFN-I
response remain ill-defined.
Here, we show that bone marrow-derived conventional dendritic
cells (BM-DCs) challenged with Candida spp. release high levels
of IFN-b, which subsequently drives an IFNAR1-dependent ac-
tivation of intracellular STAT1 and IRF7 expression. Further, IFN-
b release by BM-DCs requires dynamin-dependent phagocytosis
of fungal cells, maturation of phagolysosomes, the recognition of
fungal PAMPs by the endosomal TLR7, activation of the TLR-
specific cytoplasmic MyD88 adaptor, and intracellular Src/Syk
family kinase signaling pathways. To our knowledge, this is the
first demonstration that a TLR7-dependent pathway is involved in
the recognition of Candida spp. and mediates activation of IFN-I
signaling by a fungal pathogen. Furthermore, in a mouse model of
disseminated candidiasis we show that IFN-I signaling promotes
persistence of C. glabrata in the host. Our results highlight the




All of the animal experiments were discussed and approved through the
University of Veterinary Medicine Vienna institutional ethics committee
and carried out in accordance with animal experimentation protocols ap-
proved by the Austrian law (GZ 680 205/67-BrGt/2003).
Fungal strains and growth conditions
C. albicans clinical isolate SC5314 (15), C. glabrata clinical isolate
ATCC2001 (CBS138) (16), and Candida dubliniensis clinical isolate
CD36 (17) were used in this study. Fungal cells were grown to the loga-
rithmic growth phase in single-use, pyrogen- and endotoxin-free sterile
flasks as described previously (8). UV-treated Candida cell suspensions
were prepared by treating an aliquot of the Candida infection suspension
with 999 mJ/cm2 in a Stratalinker (Stratagene, La Jolla, CA).
Mouse models and genetic backgrounds
All of the micewere derived from the C57BL/6 background and housed under
specific pathogen-free conditions according to Federation of Laboratory
Animal Science Associations guidelines (18). IFNAR12/2 (19), Toll/IL-1R
domain-containing adapter-inducing IFN-b (TRIF) (lps2)2/2 (20), TLR22/2
(21), TLR42/2 (22), TLR92/2 (23), MyD882/2 (24), and IRF12/2 (25) mice
were housed at the animal facility of the University of Veterinary Medicine
Vienna. TLR22/2, TLR42/2, TLR92/2, and MyD882/2 mice were kindly
provided by Dr. Shizuo Akira, Osaka University, Osaka, Japan. Bone marrow
from dectin-12/2 (26) and corresponding wild-type (WT) mice were gen-
erously supplied by Dr. G. Brown, University of Aberdeen, Aberdeen, U.K.
WT C57BL/6 mice used as controls and CD11b2/2 (27) and TLR72/2 (28)
mice were purchased from The Jackson Laboratory.
Cell culture of primary innate immune cells differentiated from
bone marrow
BM-DCs and bone marrow-derived macrophages (BMDMs) were differ-
entiated from mouse bone marrow cultured for 7–8 d in GM-CSF as de-
scribed previously (29), and cell surface markers of the BM-DC
preparations were assessed by flow cytometry for expression of CD4, CD8,
CD11b, Ly-6c, CD11c, MHC class II, CCR2, Mac3, and CX3CR1. (Sup-
plemental Table I for results). More than 95% of the cells were CD11b+ but
CD82, CD42, CX3CR12, Mac32, and CCR22. Our GM-CSF–driven bone
marrow culture contains ∼64% DCs or Ly-6C+ monocytes, precursors of
DCs (33% conventional DCs, 6% monocyte-derived inflammatory DCs,
and 25% inflammatory monocytes). The remaining 27% of the cells were
monocytes/macrophages (Ly-6C2/CD11c2/CD11b+/), which we show fail
to release IFN-b or to modulate expression of IFN-I–regulated genes such
as inducible NO synthase (iNOS) in response to Candida (Supplemental
Fig. 1B). In agreement with previous reports (30), we did not obtain any
contaminating plasmacytoid DCs under these differentiation conditions.
Coculture of innate immune cells with fungi or cell wall
extracts
Fungal–mammalian cell coculture was performed at a target-to-effector
ratio of 2:1, exactly as described previously (29). Pretreatment of BM-
DCs with inhibitor molecules (dynasore, cytochalasin D, PP2, PP3, R406,
bafilomycin A1, or chloroquine) or vehicle was carried out at 37˚C (5%
CO2) for 30 min prior to stimulation. Inhibitor final concentrations were 80
mM for dynasore and 8 mM for cytochalasin D (Sigma-Aldrich, St. Louis,
MO), 25 mM for PP2 and PP3 (Calbiochem, La Jolla, CA), 4 mM for R406
(a kind gift from Rigel Pharmaceuticals, San Francisco, CA), 25 or 50 nM
for bafilomycin A1 (Sigma-Aldrich), and 10 or 50 mM for chloroquine
(Sigma-Aldrich). Pretreatment of BM-DCs with the indicated concen-
trations of synthetic oligodeoxynucleotides (IRS661 and IRS954) or
a nonspecific oligonucleotide control (CTRL_IRS) were carried out at 37˚
C for 60 min prior to stimulation. IRS661, IRS954, and CTRL_IRS were
synthesized by TIB Molbiol (Berlin, Germany) as described previously
(31). Stimulation of BM-DCs with cell wall components were performed
with 100 mg/ml b-glucans from Saccharomyces cerevisiae (Calbiochem),
100 mg/ml Curdlan, a high-m.w. b-1,3-glucan from Alcaligenes faecalis
(WAKO Chemicals, Neuss, Germany), or 0.1 mg/ml “TLR-grade” LPS
from Salmonella minnesota (Sigma-Aldrich). All of the treatments with
Candida or fungal cell wall extracts were carried out in the presence of 30
mg/ml polymyxin B (Sigma-Aldrich) to neutralize endotoxins (32).
Reverse transcription and real-time PCR analysis
RNA sample preparation, reverse transcription, and real-time PCR were
performed as described previously (29) using the following primers: mouse
GAPDH, forward59-CATGGCCTTCCGTGTTCCTA-39 and reverse 59-GCG-
GCACGTCAGATCCA-39 (RTPrimerDB, http://medgen.ugent.be/rtprimerdb/
index.php); mouse IFN-b, forward 59-TCAGAATGAGTGGTGGTTGC-39
and reverse 59-GACCTTTCAAATGCAGTAGATTCA-39 (33);mouse iNOS,
forward 59-GTTCTCAGCCCAACAATACAAGA-39 and reverse 59-GTGGA-
CGGGTCGATGTCAC-39 (Harvard Primer database, http://pga.mgh.harvard.
edu/primerbank/);mouse IRF7, forward 59-CTGGAGCCATGGGTATGCA-39
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and reverse 59-AAGCACAAGCCGAGACTGCT-39 as determined using the
sequence analysis software Vector NTI (Invitrogen, Carlsbad, CA).
For relative quantification purposes, efficiencies of the individual PCR
reactions were determined by the LinReg method (34). Results are ex-
pressed as the fold expression (R) of the gene of interest (IFN-b) versus the
expression of a housekeeping gene (GAPDH) in treated (t) versus un-






E is the PCR efficiency and Ct is the number of cycles to the threshold
fluorescence.
Immunodetection
Sample preparation and immunoblotting were performed as described
previously (29). Blots were probed with anti-STAT1 Abs recognizing
phospho-Tyr701, anti–phospho-ERK Abs (Cell Signaling, Danvers, MA),
anti-IRF3 and anti-p38 Abs, (Santa Cruz, Santa Cruz, CA), or anti–C-
terminal STAT1 sera, a kind gift from Pavel Kovarik (35). Immune com-
plexes were detected with an infrared-labeled secondary Ab (LI-Cor,
Lincoln, NE). Analysis was performed using the infrared imaging system
Odyssey (LI-Cor) according to conditions recommended by the manufac-
turer.
Cytokine measurements by ELISA and phagocytosis assays
The amount of IFN-b released in cell culture supernatants was assayed
using the VeriKine mouse IFN-b ELISA kit (R&D Systems, Minneapolis,
MN) according to the manufacturer’s instructions. Phagocytosis assays
were performed as described previously (36) using the following mod-
ifications. Briefly, C. glabrata cells were labeled with 10 mM Alexa Fluor
488 C5 maleimide (Invitrogen) in 100 mM HEPES buffer (pH 7.5) for 15
min at room temperature. Labeled C. glabrata were washed in HEPES
buffer and kept until use. BM-DCs were treated with inhibitors or vehicle
at 37˚C (5% CO2) for 30 min prior to the assay and then precooled on ice.
After 20 min, Alexa Fluor 488-labeled C. glabrata in ice-cold DMEM was
added at a target-to-effector ratio of 2:1, and samples were incubated at 37˚
C (5% CO2) for 45 min to allow for phagocytosis to occur. Phagocytosis
was terminated by chilling plates on ice, where they remained during
detaching and fixation in 1% formaldehyde. Fluorescence of extracellular
C. glabrata was quenched by addition of 0.4% trypan blue. Negative
controls for phagocytosis were left on ice during the whole process. Du-
plicate samples were subjected to flow cytometry analysis, gating on Alexa
Fluor 488/BM-DC populations with internalized C. glabrata. The per-
centage of phagocytosis was determined as follows: (inhibitor-treated BM-
DCs with C. glabrata at 37˚C 2 inhibitor-treated BM-DCs with C.
glabrata at 4˚C)/(vehicle-treated BM-DCs with C. glabrata at 37˚C 2
vehicle-treated BM-DCs with C. glabrata at 4˚C) 3 100. Results are
expressed as the mean6 SD of the percentage of ingestion (the percentage of
BM-DCs containing one or more yeast cells).
Animal model of disseminated candidiasis
WT (C57BL/6) mice and IFNAR12/2 mice were injected i.v. with 53 107
CFU C. glabrata per 25 g of mouse weight. Infected mice were euthanized
at days 7, 14, and 21 postinfection (n = 5 mice per time point) to determine
the fungal burden in spleen, liver, kidney, and brain. Organs were asepti-
cally collected and homogenized in sterile PBS. Homogenate dilutions
were plated in triplicate on yeast peptone dextrose agar plates containing
antibiotics. After a 2-d incubation at 30˚C, C. glabrata colonies were
counted. Results are expressed as CFU per gram of tissues.
Statistical analysis
Statistical analysis of data was performed using the Prism graphing and
analysis software. Comparison of two groups was done with the Student
t test (in vitro experiments) or with the nonparametric t test (Mann–Whitney
U test) for animal experiments. A p value, 0.05 was considered significant.
Results
Candida spp. trigger IFN-b release in BM-DCs and induce
IFN-I–specific genes
Phagocytes of the innate immune system such as macrophages and
DCs can release IFNs-I in response to various microbial pathogens
(9, 10). To investigate the molecular mechanisms of IFN-I re-
sponse elicited by Candida spp., we used in vitro cell culture
models of primary mouse BM-DCs or BMDMs challenged with
Candida spp. We used C. albicans and C. dubliniensis, two di-
morphic Candida spp., or C. glabrata, existing exclusively in the
yeast form. mRNA levels as well as IFN-b protein release were
measured by quantitative real-time PCR or ELISA, respectively.
All three Candida spp. strongly stimulated IFN-b mRNA ex-
pression in BM-DCs after 3 h, when compared with that in
unstimulated BM-DCs (Fig. 1A). ELISA assays confirmed that
the increase in IFN-b expression correlated with the release of
IFN-b by Candida-infected BM-DCs (Fig. 1B). Notably, both UV-
inactivated C. albicans cells and the yeast S. cerevisiae (Supple-
mental Fig. 1A) triggered IFN-b production. Interestingly, how-
ever, the response was cell-type–specific and restricted to certain
innate immune cells, because we failed to detect IFN-b mRNA
induction in BMDMs cocultured with C. glabrata, although they
still induced IFN-b and iNOS mRNA, an IFN-I–regulated gene, in
response to LPS (Supplemental Fig. 1Ba, 1Bb). Peritoneal mac-
rophages, neutrophils, or splenic DCs also did not release IFN-b
in response to C. glabrata challenge (Supplemental Fig. 1C).
Remarkably, C. glabrata consistently showed the highest potency
in stimulating IFN-b mRNA expression and subsequent cytokine
release (Fig. 1A, 1B). Hence, we chose C. glabrata cells as the
main pathogen stimulus in further experiments to investigate the
mechanisms of IFN-I response to Candida spp. by BM-DCs.
A hallmark of the IFN-I response is its ability to induce ex-
pression of a large number of effector genes (i.e., IFN-I–stimulated
genes). Indeed, IFN-b released in the first wave binds to its own
receptor IFNAR, activating the STAT1 and STAT2 transcription
factors and thereby triggering expression of typical IFN-I target
genes such as IRF7.
Because mouse BM-DCs express IFNAR, we asked whether the
initial IFN-b release observed upon Candida spp. challenge can
induce IFN-I signaling in an autocrine/paracrine fashion. Thus,
WT BM-DCs or BM-DCs lacking the IFNAR1 subunit of IFNAR
(IFNAR12/2) were cocultured with Candida spp. or left unsti-
mulated for 2 h, after which protein extracts were prepared and
FIGURE 1. Candida species induce a IFN-I response in mouse BM-
DCs. A and D, WT BM-DCs or BM-DCs lacking the IFNAR1 subunit of
the IFN-I receptor (IFNAR12/2) were infected with the indicated Candida
spp. or left untreated for the indicated time, after which cell lysates were
harvested and RNA or protein extracts were prepared. A and B, IFN-b
expression was measured by real-time PCR after 3 h of coculture (A) or by
ELISA after 24 h of coculture (B). C, Phosphorylated STAT1 was detected
by immunoblotting of protein extracts prepared after 2 h of Candida spp.–
BM-DC coculture (upper panel), and blots were reprobed with polyclonal
anti-STAT1 Abs to assess equal loading between lanes (lower panel). D,
IRF7 gene expression was measured by real-time PCR after 24 h of co-
culture. Real-time PCR results are expressed as fold increase of mRNA
expression over untreated BM-DCs. ELISA results are expressed as
picograms of IFN-b per milliliter of cell culture supernatant. Data pre-
sented are from one experiment representative of at least three independent
experiments.
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STAT1 activation was verified by immunodetection using
phospho-specific Abs. In WT BM-DCs cocultured with Candida,
IFN-b release strictly correlated with STAT1 phosphorylation
(Fig. 1C) as well as with the activation of IRF7 transcription, a
typical IFN-I–regulated gene (Fig. 1D). By contrast, in IFNAR12/2
BM-DCs stimulated with C. glabrata, no STAT1 phosphorylation
was seen (Fig. 1C), and IRF7 transcription was not induced (Fig.
1D). Consistent with the absence of IFN-b release in BMDMs
challenged with C. glabrata, no STAT1 activation was observed
(Supplemental Fig. 1Bc). As expected, STAT1 activation was still
detected in BM-DCs lacking the IFN-g gene (IFN-g2/2), which
can signal through STAT1 phosphorylation (Supplemental Fig.
1D). All together, these data demonstrate that Candida spp. trigger
a first wave of IFN-b in BM-DCs, thereby activating an IFN-I
response in an IFNAR1-dependent fashion.
Candida-induced IFN-b release is partially dependent on
Src/Syk kinase signaling
The main PRRs involved in Candida spp. recognition belong to
the C-type lectin and TLR families (3). C-type lectins, like other
ITAM-bearing receptors, signal through intracellular Syk and Src
family kinases. We thus reasoned that PP2, an inhibitor of Src
family kinases, and R406, a highly specific inhibitor of the Syk
kinase, may impair the IFN-b response to Candida spp. Indeed,
pretreatment of BM-DCs with R406 prior to C. glabrata stimu-
lation significantly decreased the IFN-b release by ∼80% (Fig. 2A,
left panel). Likewise, PP2 strongly inhibited the C. glabrata-
triggered IFN-b release to ∼12% of the level observed when
BM-DCs were pretreated with DMSO vehicle alone; as a control,
PP3, the inactive analogue of PP2, had no significant effect (Fig.
2A, right panel). Thus, these results unequivocally show that both
intracellular Src and Syk signaling pathways are required to elicit
the IFN-b release in response to fungal cells. Moreover, the
data imply the involvement of ITAM-bearing receptors in this
signaling process.
The C-type lectin dectin-1, a b-1,3-glucan receptor, has been
known as one of the major receptors mediating Candida spp.
recognition (37). Surprisingly, however, BM-DCs lacking the
dectin-1 receptor still released IFN-b upon C. glabrata challenge
(Fig. 2B, left panel). Thus, these results show that dectin-1 is not
involved in mediating the Candida-induced IFN-b release. In
addition to dectin-1, CD11b (integrin aM) can also bind C. albi-
cans b-glucans, is present in the phagosome upon Candida
phagocytosis, and also activates the Src family and Syk kinases
(38). Thus, we investigated the potential role of CD11b in the
IFN-b response by challenging CD11b-deficient BM-DCs with C.
glabrata. Even in the absence of CD11b, IFN-b release was ob-
served, albeit slightly reduced, suggesting that this b-glucan re-
ceptor is not the main receptor involved in triggering the initial
IFN-b release in BM-DCs infected with C. glabrata. Furthermore,
no significant IFN-b release was observed when BM-DCs were
pretreated with b-glucan extract from S. cerevisiae or Curdlan
(Fig. 2C). However, these cells readily responded to LPS, which
was used as a positive control for active PRR signaling via TLR4.
Additional potential PAMPs such as chitin or mannan failed to
induce detectable IFN-b levels in BM-DCs (data not shown).
Thus, our data show that neither dectin-1 nor CD11b or other
PRRs for known cell wall PAMPs mediate the initial IFN-b
release upon Candida spp. challenge. Nevertheless, it still required
activation of intracellular Src family and Syk kinase signaling
pathways.
Beside their role as intracellular adaptors for certain PRRs, Src
family and Syk kinases are also involved in mediating phagocytic
processes. Therefore, we assayed their involvement in phagocy-
tosis using a flow cytometry-based analysis of the percentage of
BM-DCs having phagocytosed at least one Alexa Fluor 480-
labeled C. glabrata with or without inhibitor pretreatment. Pre-
treatment with the Src kinase inhibitor PP2 had no significant
effect on the phagocytic properties of BM-DCs (data not shown).
By contrast, only 60% of the BM-DCs pretreated with the Syk
inhibitor R406 contained at least one C. glabrata cell when
compared with 100% of BM-DCs having engulfed at least one C.
glabrata in vehicle (DMSO)-treated BM-DCs (Fig. 2D). There-
fore, these data suggest that Syk kinase activation promotes IFN-b
release by contributing to the invasion process in BM-DCs
phagocytosing fungal pathogens.
Candida-induced IFN-b release is TLR2- and
TLR4-independent
The second main class of PRRs involved in sensing and recogniz-
ing Candida spp. is the TLR family. In particular, TLR2 and TLR4
are thought to be involved in Candida recognition and reported to
be essential for survival toCandida infections in mice (2). Thus, we
FIGURE 2. Role of Syk/Src kinases and b-glucan receptors. A, WT BM-
DCs were preincubated with a Syk kinase inhibitor (R406), an inhibitor of
Src family kinases (PP2), and an inactive homologue (PP3) or vehicle
(DMSO) at 37˚C for 30 min prior to coculture with C. glabrata or media
alone for 6 h. IFN-b release into the cell culture medium was measured by
ELISA. B, WT BM-DCs or BM-DCs lacking dectin-1 (dectin-12/2) or
CD11b (CD11b2/2) were cocultured for 6 h with C. glabrata or left unsti-
mulated. IFN-b release was measured by ELISA. C, BM-DCs were stimu-
lated with either b-glucan preparations (S. cerevisiae b-glucans) or Curdlan
in media containing polymyxin B, or with LPS for 4 h, or left untreated as
a control. IFN-b release into the cell culture medium was measured by
ELISA. ELISA results are expressed as picograms of IFN-b per milliliter of
supernatant. Data presented are from one experiment representative of three
independent experiments. D, WT BM-DCs were preincubated with a Syk
kinase inhibitor (R406) or vehicle (DMSO) prior to coculture with Alexa
Fluor 480-labeledC. glabrata at 37˚C or 4˚C (adherence control) for 45min.
Cells were collected, and the number of BM-DCs containing at least one
C. glabrata was analyzed by flow cytometry. Results are expressed as per-
centage of ingestion (the percentage of BM-DCs containing one or more
yeast cells). B andC, Data presented are from one experiment representative
of at least three independent experimental repeats. A and D, Data presented
are the mean6 SD of data from three independent experiments. *p, 0.05,
***p # 0.0005, unpaired, two-tailed t test.
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investigated whether these receptors were involved in the IFN-b
response to Candida using BM-DCs lacking either TLR2 (TLR22/2)
or TLR4 (TLR42/2). Surprisingly, when WT and mutant BM-
DCs were infected with C. glabrata, IFN-b release was stimu-
lated to similar or even higher levels (Fig. 3A, 3B, left panels).
Accordingly, a strong STAT1 activation was observed in both WT
and mutant BM-DCs (Fig. 3B, right panel), demonstrating that the
IFN-I response to Candida spp. is bypassing the known TLR2 or
TLR4 signaling pathways.
IFN-b release of BM-DCs requires phagocytosis and MyD88
activation
TLRs use either MyD88 (e.g., TLR1, TLR2, TLR6, TLR7, TLR8,
and TLR9), TRIF (in the case of TLR3), or both, as in the case of
TLR4 (39), as intracellular signaling adaptors. To further in-
vestigate the possible involvement of TLR signaling in the IFN-b
release, we used BM-DCs lacking either one of these signaling
adaptors. Remarkably, BM-DCs lacking MyD88 (MyD882/2)
failed to release any IFN-b after C. glabrata (Fig. 4A, left panel)
or C. albicans (Supplemental Fig. 2E) challenge. Accordingly,
MyD882/2 BM-DCs cocultured with C. glabrata also failed to
mount the subsequent IFN-I response, as evident from a much
weaker STAT1 phosphorylation when compared with that of the
WT BM-DCs (Fig. 4A, right panel). By sharp contrast, a lack of
TRIF did not impair the IFN-b release after Candida challenge
(Fig. 4B). These data exclude a role for TLR3 but unequivocally
demonstrate a strict requirement for a TLR/MyD88 signaling
mechanism in sparking the first wave of IFN-b release in BM-DCs
facing fun-
gal invasion.
In mice, both surface TLRs (TLR1, TLR2, TLR4, TLR5, and
TLR6) and phagosomal TLRs (TLR7–9) signal through theMyD88
adaptor. To further narrow down the list of candidate TLRs rec-
ognizing Candida spp. for triggering IFN-b, we used dynasore,
a specific and potent small-molecule inhibitor of the GTP-binding
protein dynamin required for proper constriction of clathrin-coated
vesicles during endocytosis and phagocytosis (40). Strikingly,
dynasore pretreatment of BM-DCs prior to Candida addition
completely abolished IFN-b release to the level of unstimulated
BM-DCs. No inhibition was observed in BM-DCs pretreated with
vehicle (DMSO) only (Fig. 4C). The effect of dynasore treatment
was not caused by loss of cell viability, as verified by life-stain-
ing (data not shown). It was also specific as confirmed by the re-
maining ERK activation upon fungal challenge in treated BM-
DCs (Supplemental Fig. 2A), the latter being a hallmark of cell
surface PRR activation on immune cells uponCandida recognition.
Cytochalasin D, a well-known inhibitor of actin polymerization
blocking endocytosis, also prevented release of IFN-b in C. glabrata-
challenged BM-DCs (Fig. 4D). Thus, IFN-b induction by Candida
spp. in BM-DCs requires dynamin-dependent phagocytosis, strongly
suggesting that the activation of MyD88 demands PAMP recognition
by phagosomal TLRs.
Candida-induced IFN-b release requires phagosome
acidification and TLR7
Endosomal maturation through acidification is required for acti-
vation of intracellular TLRs by their specific ligands and sub-
sequent stimulation of their adaptor MyD88 in the presence of
PAMPs (41). Thus, we asked whether bafilomycin A1 or the an-
timalarial drug chloroquine, both compounds specifically inhibit-
ing endosome acidification, would also block Candida-induced
IFN-b release. Strikingly, pretreatment of BM-DCs with 10 mM
chloroquine or 25 nM bafilomycin A1 strongly inhibited IFN-b re-
FIGURE 3. IFN-b release triggered by C. glabrata is TLR2- and TLR4-
independent. A and B, WT BM-DCs or BM-DCs lacking TLR2 (TLR22/2)
or TLR4 (TLR42/2) were cocultured for 4 h with C. glabrata or left unsti-
mulated, and IFN-b release was measured by ELISA (left panel) or phos-
phorylated STAT1 was detected by immunoblotting of extracts prepared
after 2 h of C. glabrata–BM-DC coculture; blots were reprobed with poly-
clonal anti-STAT1 Abs to verify equal loading (right panel). ELISA results
are expressed as picograms of IFN-b per milliliter of cell culture medium.
Data presented are from one experiment representative of three independent
experiments.
FIGURE 4. IFN-b release requires phagocytosis and MyD88 activation.
A, WT BM-DCs or BM-DCs lacking the MyD88 signaling adaptor
(MyD882/2) were cocultured for 4 h with C. glabrata or left unstimulated,
IFN-b release was measured by ELISA (left panel) or phosphorylated
STAT1 was detected by immunoblotting of protein extracts prepared after
3.5 h of C. glabrata–BM-DC coculture, and blots were reprobed with
polyclonal anti-STAT1 Abs to assess equal loading between lanes (right
panel). B, WT BM-DCs or BM-DCs lacking the TRIF signaling adaptor
(TRIF2/2) were cocultured with C. glabrata or left unstimulated. IFN-b
release was measured by ELISA after 4 h. C and D, WT BM-DCs pretreated
with either dynasore (C), cytochalasin D (D), or vehicle (DMSO) for 30 min
were cocultured with C. glabrata or left untreated; IFN-b production was
measured by ELISA after 4 h. ELISA results are expressed as picograms of
IFN-b per milliliter of cell culture medium. Western blot data presented are
from one experiment representative of at least three independent experi-
ments. ELISA data presented are the mean 6 SD of data from three in-
dependent experiments. ***p # 0.0005, unpaired, two-tailed t test.
3108 CANDIDA spp. DRIVE PHAGOSOMAL TYPE I IFN HOST RESPONSE
 at M









lease upon stimulation with C. glabrata (***p # 0.0001) (Fig.
5A), demonstrating a pivotal role for endosomal TLRs in IFN-b
release in BM-DCs. The effect of bafilomycin A1 or chloroquine
treatment was not caused by loss of cell viability, as verified by
life-staining (data not shown). Moreover, BM-DCs still activated
intracellular ERK upon C. glabrata challenge (Supplemental Fig.
2B) (a typical response of innate immune cells to Candida chal-
lenge originating from activated cell surface PRRs) or released
TNF-a upon Candida challenge (Supplemental Fig. 2C).
In mice, the endosomal TLRs requiring MyD88 to recognize
PAMPs comprise TLR7, TLR8, and TLR9, but TLR7 and TLR9
seem to account for most of the signaling. To investigate the con-
tribution of these PRRs, we used BM-DCs lacking either TLR7
(TLR72/2) or TLR9 (TLR92/2). Surprisingly, the IFN-b release
was fully abrogated in BM-DCs lacking TLR7 (Fig. 5B, left panel)
but was stimulated to levels similar to those of WT cells in BM-
DCs lacking TLR9 (Fig. 5B, right panel). The absence of response
to C. glabrata in TLR7-deficient BM-DCs was not due to a gen-
eral defect in IFN-b production, because these cells still released
IFN-b to WT comparable levels upon LPS stimulation (Supple-
mental Fig. 2D). Furthermore, specifically blocking TLR7 ac-
tivation using synthetic oligodeoxynucleotides (e.g., IRS661, an
antagonist of TLR7, or IRS954, which inhibits both TLR7 and
TLR9) strongly decreased IFN-b production upon fungal chal-
lenge in a dose-dependent fashion (Fig. 5C). The unspecific
control oligodeoxynucleotide CTRL_IRS had no detectable or
significant effect on IFN-b production (Fig. 5C). To further
identify the transcription factors involved in the Candida-induced
IFN-b release, we used BM-DCs lacking either IRF1, IRF3, or
IRF7. The IFN-b release was only significantly reduced in the
absence of IRF1 (Fig. 5D) but was unaffected in BM-DCs lacking
IRF3 or IRF7 (data not shown).
Integrated model of IFN-I response to fungal pathogens in
BM-DCs
On the basis of our collective data, we propose the following model
for the Candida-induced IFN-b signaling pathway operating in
BM-DCs (Fig. 6). Adhesion and recognition of Candida spp. at
the surface of innate immune cells initiates dynamin-dependent
phagocytosis. Maturation and acidification of the phagolysosome
allow for processing of TLR7, which is subsequently activated by
its cognate PAMP ligands, most likely fungal-specific RNAs, to
recruit and activate cytoplasmic MyD88 and subsequently the
IRF1 transcription factor, ultimately triggering the IFN-b release.
Other as yet unknown pathways acting through Syk/Src family
kinase signaling may also contribute to the induction of IFN-I
response in BM-DCs. Taken together, the results provide the first
demonstration of an IFN-b release by BM-DCs in response
to phagosomal Candida recognition, hence revealing a novel role
for endosomal TLRs in fungal recognition.
FIGURE 5. IFN-b release requires activation of phagosomal TLR7. A,
BM-DCs pretreated for 30 min with either bafilomycin A1 (bafiloA1),
chloroquine (ChQ), or vehicle alonewere coculturedwithC. glabrata for 6 h
or left untreated. IFN-b release was measured by ELISA, and results are
expressed as picograms of IFN-b permilliliter of cell culturemedium.B,WT
BM-DCs or BM-DCs lacking either TLR7 (TLR72/2) or TLR9 (TLR92/2)
were cocultured for 6 h with C. glabrata or left unstimulated, and IFN-b
release was measured by ELISA. C, BM-DCs were pretreated for 60 min
with the indicated concentrations of synthetic inhibitory oligodeoxynu-
cleotides (IRS661 or IRS954) or with an unspecific oligodeoxynucleotide
(CTRL_IRS) as a control. Subsequently, BM-DCs were cocultured for 6 h
with C. glabrata or left unstimulated. IFN-b release was measured by
ELISA, and results are expressed as picograms of IFN-b per milliliter of cell
culture medium. D, WT BM-DCs or BM-DCs lacking the IRF1 transcrip-
tion factor (IRF12/2) were cocultured for 6 h with C. glabrata or left
unstimulated, and IFN-b release was measured by ELISA. A–D, Values
represent the mean 6 SD of three independent experiments performed in
triplicate. **p # 0.005, ***p # 0.0001, unpaired, two-tailed t test.
FIGURE 6. Model of IFN-b response to Candida spp. in mouse BM-
DCs. In BM-DCs, a dynamin-dependent phagocytosis step, Syk/Src-de-
pendent-signaling, followed by endosome acidification, leads to the activa-
tion of TLR7, probably by Candida RNAs, thereby stimulating a MyD88–
IRF1-dependent signaling pathway required for the initial release of IFN-b
and the subsequent induction of an IFN-I response to fungal infection.
Actions of inhibitors (dynasore, R406, PP2, bafilomycin A1, and chloro-
quine) used in this study are indicated on their specific targets.
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IFN-I response promotes C. glabrata persistence in host tissues
To investigate the role of this IFN-I in the host response to Can-
dida, we used a model of disseminated candidiasis and compared
the outcome of C. glabrata infections in WT mice versus those
in IFNAR12/2 mice, which are unresponsive to IFN-I. Because
systemic C. glabrata infection is normally not pathogenic for
immunocompetent mice (42, 43), we used tissue fungal burden to
assess persistence. At day 7 postinfection, CFU counts in spleen,
liver, and brain of IFNAR12/2 mice were significantly lower
than those in WT organs (Fig. 7A). No significant difference in C.
glabrata CFU counts was observed in kidney of WT versus
IFNAR12/2 mice (data not shown). At days 14 and 28 post-
infection, CFU counts were still detectable in organs of infected
animals, although without statistically significant differences be-
tween WT and IFNAR12/2 tissues (data not shown). Interestingly,
a significantly more pronounced splenomegaly was observed in
infected IFNAR12/2 mice in comparison with that of infected WT
mice at day 7 (Fig. 7B), suggesting a stronger immune response
in the spleen of IFNAR12/2 mice than in the spleen of WT
animals at day 7 postinfection.
Discussion
In this report, we show for the first time, to our knowledge, that
Candida spp. trigger an IFN-I response in mouse BM-DCs. We
identify TLR7 as the essential PRR activating this immune re-
sponse in a MyD88-dependent fashion from within maturing
phagolysosomes. Because of the phagocytic and microbicidal
properties, innate immune cells are the first line of defense against
many microbial pathogens. In addition, they are producers of
IFNs-I, a family of cytokines specialized in coordinating the cross
talk between the innate and adaptive immune responses to mi-
crobial or viral infections (9). Therefore, we studied the capa-
bilities of several innate immune cell types such as bone marrow-
derived neutrophils or macrophages, peritoneal macrophages, and
bone marrow or splenic DCs to respond to fungal challenges by
producing IFN-b using an in vitro coculture interaction system.
However, only mouse BM-DCs are able to release IFN-b but not
IFN-a (data not shown) in response to Candida spp. Notably,
others also observed detectable IFN-b induction upon challenge
with C. albicans in flt3-differentiated DCs but only a weak but
significant induction of IFN-a gene transcription in BM-DCs
stimulated with the yeast form of C. albicans. This discrepancy
may be caused by differences in the protocols used to prepare the
BM-DCs (11). Markedly, both BMDMs and BM-DCs release
IFN-b when challenged with another prominent fungal pathogen,
Cryptococcus neoformans (13). Under our experimental con-
ditions, the IFN-I response to Candida is highly cell-type–
specific within innate immune cells, because peritoneal or
BMDMs as well as neutrophils or splenic DCs challenged by
Candida fail to release detectable amounts of IFN-b. Thus, our
results are consistent with reports about distinct and cell-type–
specific cytokine responses between BMDMs and myeloid den-
dritic cells (44–46), suggesting that different innate immune cells
may have distinct repertoires to sense and to respond to micro-
bial PAMPs, depending on the differentiation procedure used to
obtain the cells in vitro or the host tissue environment in vivo. This
may help to fine-tune the host defense and immune surveillance.
We show in this study that other Candida spp. such as C.
dubliniensis. and C. glabrata also spark IFN-b release. Inter-
estingly, C. glabrata, a nondimorphic yeast-like species, appears as
a much better trigger for IFN-b than the pleomorphic filamentous
speciesC. albicans orC. dubliniensis. Thismay relate to the fact that
C. glabrata can persist in the host for prolonged periods (42, 47),
whereas C. albicans normally efficiently kills host cells after a few
hours or escapes from the phagosome (48, 49). Hence, it seems
feasible that the ability of C. albicans to escape the phagosome,
subsequently causing host cell lysis, may explain the weaker in-
duction of IFN-I response versus C. glabrata, the latter leading to
strong IFN-b release due to its persistence in the host immune cells.
b-Glucan preparations stimulate the release of a number of
cytokines such as TNF-a, IL-2, or IL-12 from innate immune cells
(38), and they can induce BM-DC maturation in humans (50) as
well as in mice (51). b-Glucan drives BM-DC maturation at least
in part through dectin-1, which is considered a major PRR for
glucans (37). However, in this study we show that the C.
glabrata-induced IFN-b release is independent of dectin-1 and
CD11b, both acting as b-glucan receptors accumulating at the site
of Candida uptake by macrophage phagocytosis (52). Further-
more, we tend to exclude the involvement of other unknown
b-glucan receptors, because all of the b-glucan preparations that
we used, namely, b-1,3- and b-1,6-glucan extracts obtained from
the S. cerevisiae cell wall, and Curdlan, a linear b-1,3-glucan
polymer, fail to trigger an IFN-b release in BM-DCs. Likewise,
mannan and chitin are also inactive under these conditions. Hence,
in contrast to LPS from the cell wall of Gram-negative bacteria,
fungal cell wall extracts do not induce IFN-b release in innate
immune cells, despite being a rich source of fungal PAMPs for
other cytokine responses (2). However, care has to be taken when
performing these experiments, because many commercial and
custom-made cell wall preparations contain minute LPS con-
tamination, which may lead to conflicting interpretations of
results. Therefore, all of our cytokine experiments in primary cells
were carried out in the presence of polymyxin B, which alleviates
the LPS contamination problem (32)
By specifically inhibiting dynamin, we demonstrate that fungal
phagocytosis is a mandatory prerequisite for IFN-b release.
Similarly, inhibition of Src family kinases also strongly blocks
IFN-b release. Notably, phosphorylation of cortactin and dynamin
by Src kinase is required for activation of endocytosis in epithelial
cells (53), and both cortactin and dynamin are essential for Can-
dida internalization in epithelial cells (54). Furthermore, Syk ki-
nase activation is also in part necessary for IFN-b production.
Although in this context, Syk function on IFN-b release is not
dectin-1– or CD11b-dependent, it is relevant for mediating
FIGURE 7. IFN-I signaling promotes C. glabrata persistence in host
tissues. WT and IFNAR12/2 mice were i.v. infected with 5 3 107 CFU
C. glabrata on day 0. A, On day 7 postinfection, fungal burdens were
determined by culture from tissue homogenates of five animals per group.
B, Average spleen weight of WT and IFNAR12/2 mice on day 7 post-
infection with C. glabrata. Spleen weights of three mice injected with PBS
only are shown as controls. Nonparametric t test (Mann–Whitney U test)
was performed on data sets. *p , 0.05, **p , 0.01.
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Candida phagocytosis. Whether it occurs through its role in
integrin-mediated signal transduction (55), as signaling adaptor of
ITAM-bearing receptors, or as mediator of phagocytic processes
(56) is under investigation. Nonetheless, our data emphasize the
pivotal importance of phagocytosis and thus compartmentalized
ligand–receptor interactions for orchestrating the IFN-I host re-
sponse to Candida spp. as for other microbial pathogens (41).
Using BM-DCs lacking the TLR adaptors TRIF or MyD88, we
demonstrate that the C. glabrata-induced IFN-b release strictly
requires MyD88 signaling. Hence, our findings are consistent
with the model of a MyD88 pathway mediating the cytokine re-
sponse of inflammatory DCs to yeast (11). Our data further
strengthen the importance of inflammatory DCs in the response
against Candida infection as major producers of IFN-b. Surpris-
ingly, however, neither lack of TLR2 nor TLR4 impairs the IFN-b
release, although these PRRs appear to be critical for survival to
C. albicans dissemination in mouse models (2).
Most interestingly, our results demonstrate that TLR7 is the
main phagosomal PRR triggering an initial IFN-b release upon
Candida recognition by BM-DCs. They are in agreement with the
notion that endolysosomes are unique IFN-inducible organelles
(41). Spatial recognition of microbial ssRNA by TLR7 within en-
dosomes was first observed for viruses (9). More recently, this
mechanism was found to apply to bacterial recognition in mice
and humans (46, 57). However, this is the first report, to our
knowledge, of fungal recognition by TLR7, thus underscoring the
importance of the TLR7–MyD88–IRF1 pathway for endolysoso-
mal recognition of pathogens in BM-DCs. A potential role of
TLR7 in survival to C. albicans or any fungal microbe has yet to
be further explored. Because TLR7 recognizes ssRNA, the present
report also hints the importance of Candida-derived RNAs as
potential PAMP sources driving host immune cell activation
through the IFN-I response. Indeed, recognition of Candida DNA
by TLR9 triggers release of IL-12p40 in BM-DCs (6). In-
terestingly, Candida RNA-pulsed bone marrow and spleen DCs
undergo activation and confer protection against systemic C.
albicans infection in mice (7). Whether these properties resulted
from activation of an IFN-I response in these innate immune cells
is unknown.
Activation of the IFN-I response is critical for the maturation of
DCs into professional APCs that help to shape the magnitude and
duration of the adaptive immune response by inducing the dif-
ferentiation of Th cells (9). In general, IFNs-I can function both as
proinflammatory and anti-inflammatory cytokines, but the con-
tribution of each property to the overall host response is not well
understood (9, 58). To test the pathophysiological relevance of
IFN-I signaling in the host response to Candida infection, we
challenged mice lacking a functional IFNAR through tail vein
injections with C. glabrata. Strikingly, we show that the IFN-I
response promotes the persistence of C. glabrata in host tissues,
thus suggesting that IFN-type I is detrimental for fungal clearance
in a model of disseminated Candida infection. Notably, very little
is known as yet about the mechanisms enabling C. glabrata to
persist in host tissues, and we report in this study for the first time,
to our knowledge, that IFN-I plays a role in this process. Treat-
ment with neutralizing Abs against TNF-a indicates that this
cytokine promotes C. glabrata clearance from host tissues in the
early postinfection phase (43). When we measured TNF-a at day
7 postinfection in liver and spleen though, we were unable detect
a statistically significant difference between WT and IFNAR12/2
mice (data not shown). The more pronounced splenomegaly ob-
served in IFNAR12/2 versus WT mice in response to infections
implies that the decrease in C. glabrata persistence in IFNAR12/2
mice could be due to a higher general immune response in the
absence of IFN-I. In humans and mice, IFNs-I inhibit DC-
mediated Th17 cell differentiation (59–62). Furthermore, by
stimulating IL-10 expression and downregulating IL-12 pro-
duction, IFNs-I appear to modulate Th1/Th2 polarization favoring
reduced inflammation and host tissue damage, indicating a pro-
tective role (63). Further experiments are ongoing in our labora-
tory to decipher the molecular mechanisms of IFN-Is in promoting
C. glabrata persistence or clearance.
Taken together, our results presented in this study hint to a
crucial and as yet unrecognized role for TLR7 in fungal recog-
nition and induction of IFN-I response in mouse BM-DCs chal-
lenged with Candida spp. Our work is entirely consistent with
reports where fungal nucleic acids were recognized as PAMPs to
trigger host immune responses (5–7, 12, 57). Importantly, our data
are highly relevant for humans, because microbial RNAs induce
IFN-a release in human DCs (57). Furthermore, our results stress
the importance of IFN-I in modulating the host response to fungal
pathogens such as Candida spp. and suggest a hitherto un-
recognized general role of IFN-I in modulating fungal virulence.
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